World Health Organization Sounds Alert Over Severe Scarcity of Obesity Jabs
Fewer than a tenth of people who could benefit from weight-loss injections including Wegovy are able to get them, warns the WHO as it issues its inaugural recommendations on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for broader and more equitable availability to GLP-1 medication.
Per projections, over two billion will be obese by 2030 unless action is taken.
"Our latest guidance acknowledges that obesity is a lifelong illness that can be managed with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key hurdles to broad access to the injections that can assist patients in reducing substantial body mass, explains the body.
Skinny Jab Shortage
Even in the present most optimistic outlook, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of those who need them, per the WHO.
The guideline urges governments and firms to increase availability, by strategies such as patent sharing.
A patent on semaglutide – the core ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Obesity Injections Function
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, curb appetite and boost satiety so individuals reduce food intake.
Patients typically begin shedding pounds within a few weeks of beginning the once-weekly jabs.
Research indicates patients may regain a significant portion after a year of stopping the treatment, when their usual food cravings return.
Being above a healthy weight raises your likelihood for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight concerns people in countries worldwide and was associated with millions of fatalities worldwide in 2024, as per the health agency.
